What are the symptoms of Valley fever (coccidioidomycosis)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Valley Fever Symptoms

Valley fever (coccidioidomycosis) most commonly presents as a community-acquired pneumonia with respiratory symptoms (cough, dyspnea, chest pain), but the hallmark feature is extreme fatigue that can persist for weeks to months, often accompanied by fever, drenching night sweats, weight loss, and in some patients, distinctive skin rashes (erythema nodosum or erythema multiforme) or symmetrical joint pain in the lower extremities. 1

Primary Pulmonary Symptoms

The respiratory illness dominates the clinical picture in most symptomatic cases:

  • Cough (present in ~21% at diagnosis) 2
  • Dyspnea/shortness of breath (present in ~13% at diagnosis) 2
  • Chest pain - often sharp and pleuritic 1
  • Pneumonia-like presentation - accounting for 24-29% of community-acquired pneumonia in endemic areas 3, 1

Critical caveat: These respiratory symptoms are indistinguishable from other causes of pneumonia, making travel or residence history in endemic areas (southwestern US, parts of Mexico, Central/South America) absolutely essential for diagnosis 1.

Systemic Symptoms

Beyond the lungs, patients experience profound constitutional symptoms:

  • Extreme fatigue (~9% at diagnosis, but often the most debilitating and last symptom to resolve) 2, 1 - this frequently prevents normal work and daily activities for weeks to months
  • Fever - common but not universal 1
  • Drenching night sweats - particularly when lasting >3 weeks, this indicates more severe disease 4
  • Weight loss - especially concerning when >10% of body weight 4

Dermatologic Manifestations

Skin findings occur in two distinct patterns:

Hypersensitivity reactions (do NOT contain fungus, resolve without scarring):

  • Erythema nodosum - tender red nodules, typically on lower legs 1
  • Erythema multiforme - target-like lesions 1

Disseminated cutaneous disease (contains viable fungus, requires treatment):

  • Chronic ulcerations, plaques, nodules, or subcutaneous abscesses 1, 5
  • Can present on face or scalp 5, 6

Rheumatologic Symptoms

  • Arthralgias - multiple joints, symmetrical distribution 1
  • Predominantly lower extremities - more distal joints affected 1
  • No joint effusions - this distinguishes it from septic arthritis 1
  • Joint pain can persist 9-12 months post-diagnosis 2

Disseminated Disease Symptoms

When infection spreads beyond the lungs (0.5-2% of cases), symptoms depend on location 7:

  • Meningitis: Sustained headache, CNS symptoms 4, 1
  • Bone/joint involvement: Focal skeletal pain, osteomyelitis 1
  • Skin lesions: Chronic ulcers or abscesses (different from hypersensitivity rashes) 1

Important: Pulmonary symptoms may be minimal or completely absent in disseminated disease 1

Symptom Persistence

Recent data shows symptoms can persist well beyond acute infection 2:

  • Dyspnea and erythema nodosum remain elevated 3-6 months post-diagnosis
  • Fatigue, headache, joint pain, and weakness remain elevated 9-12 months post-diagnosis
  • Fatigue is typically the last symptom to resolve, requiring prolonged convalescence 1

Timeline for Symptom Onset

Symptoms develop within 1-4 weeks of exposure to endemic areas 1. Consider coccidioidomycosis in any patient developing community-acquired pneumonia, skin rashes, or joint complaints within a month of visiting or residing in endemic regions 1.

High-Risk Presentations Requiring Immediate Attention

Seek these red flags indicating severe disease 4:

  • Weight loss >10%
  • Night sweats >3 weeks duration
  • Infiltrates exceeding 50% of one lung or bilateral disease
  • Complement fixation titers ≥1:32
  • Underlying immunosuppression
  • Substantial cardiopulmonary comorbidities

Related Questions

What is the appropriate assessment and management plan for a patient with Valley fever (coccidioidomycosis)?
How is valley fever (coccidioidomycosis) diagnosed?
Should valley fever (coccidioidomycosis) be treated in an otherwise healthy adult with a clear chest on imaging and no respiratory symptoms?
What is the recommended treatment for valley fever?
Can valley fever cause residual lung damage after treatment?
Is it safe to prescribe isotretinoin to a patient on antiretroviral therapy, and what adjustments to the HIV regimen are needed to avoid CYP3A4 drug interactions and related toxicity?
What oral progesterone regimen is recommended for an adult woman with dysfunctional uterine bleeding and no contraindications?
What is the appropriate dose of 0.2% ropivacaine for a femoral nerve block in a 60‑kg adult male?
Given a patient with HIV and lymphoma on Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) and Pifeltro (darunavir/cobicistat) who recently received Bactrim (trimethoprim‑sulfamethoxazole) and acyclovir prophylaxis, with a CD4 count of 163 cells/µL and a detectable HIV viral load of 320 copies/mL, should PCP (Pneumocystis jirovecii pneumonia) prophylaxis with Bactrim be continued or restarted, and are any additional recommendations indicated at this time?
Is 12 mL of 0.2 % ropivacaine combined with 7 mL of 2 % lidocaine sufficient for a femoral nerve block in a 60‑kg adult male?
What is the recommended ampicillin‑sulbactam dosing for an adult with an uncomplicated urinary tract infection, and how should the dose be adjusted in renal impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.